Title : Improvement of Targeted Chemotherapy of HER2-positive Ovarian Malignant Cell Line by ZHER2-Idarubicin Conjugate: An in vitro Study.

Pub. Date : 2021 Spring

PMID : 33936221






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In the current study, we assessed the cytotoxic effects of idarubicin-ZHER2 affibody conjugate on the positive-HER2 cancer cell lines. Idarubicin erb-b2 receptor tyrosine kinase 2 Homo sapiens
2 Conclusion: The ZHER2-affibody conjugate of idarubicin has a more specific cytotoxic effect compared with idarubicin alone against HER2-overexpressing ovarian cancerous cells. Idarubicin erb-b2 receptor tyrosine kinase 2 Homo sapiens
3 Conclusion: The ZHER2-affibody conjugate of idarubicin has a more specific cytotoxic effect compared with idarubicin alone against HER2-overexpressing ovarian cancerous cells. Idarubicin erb-b2 receptor tyrosine kinase 2 Homo sapiens
4 It appears the ZHER2-affibody conjugate of idarubicin has great potential to be implicated as an innovative anti-cancer agent in future clinical trials in patients with HER2-overexpressing ovarian cancer. Idarubicin erb-b2 receptor tyrosine kinase 2 Homo sapiens